Patient-reported outcome and survival in premenopausal hormone receptor-positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real-world study

Abstract

Toremifene, a selective estrogen receptor modulator, is commonly used in China for premenopausal breast cancer patients. This real-world study aimed to compare patient-reported outcome (PRO) and survival between toremifene and aromatase inhibitor (AI) plus ovarian function suppression (OFS) in patients with moderate-/high-risk premenopausal hormone receptor (HR)-positive breast cancer. The primary endpoint was PROs, assessed using SF-36 and EQ-5D-5L questionnaires between January and March 2023. A total of 392 patients were included, with 171 receiving toremifene and 221 receiving AI. The toremifene group showed significantly higher scores in the role physical (p = 0.034) and mental health (p = 0.009) dimensions of SF-36 and lower anxiety/depression (AD) scores (p = 0.038) in EQ-5D-5L compared to AI group. The estimated 5- and 8-year disease-free survival (DFS) rates were similar in toremifene and AI groups: 96.5% versus 91.9%, and 87.4% versus 87.8% (p = 0.39), respectively. Adverse event rates were similar in two groups, except for a greater risk of endometrial thickening (p < 0.001) and a lower occurrence of morning stiffness (p < 0.001) in the toremifene compared to the AI group. Premenopausal HR-positive breast cancer patients receiving toremifene plus OFS had better role physical and mental health outcomes and lower AD dimensions than those receiving AI plus OFS. Both treatments had comparable DFS and favorable tolerability profiles.

Keywords

aromatase inhibitor / patient-reported outcome / premenopausal hormone receptor-positive breast cancer / toremifene

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263.

[2] Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat. 2016; 159(3): 395-406.

[3] Yang Y, Liu J, Peng M, et al. Introduction of a multicenter online database for non-metastatic breast cancer in China. Sci China Life Sci. 2020; 63(9): 1417-1420.

[4] International Breast Cancer Study Group, Pagani O, Gelber S, et al. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12–93 and 14–93. Ann Oncol. 2004; 15(12): 1749-1759.

[5] Qin T, Yuan ZY, Peng RJ, et al. Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis. Curr Oncol. 2013; 20(4): 196-204.

[6] Lewis JD, Chagpar AB, Shaughnessy EA, et al. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer. 2010; 116(10): 2307-2315.

[7] Lu J, Li H, Guo P, et al. The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis. Onco Targets Ther. 2017; 10: 5429-5437.

[8] Lan B, Ma F, Zhai X, et al. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. Int J Cancer. 2018; 143(1): 184-189.

[9] Lan B, Ma F, Chen S, et al. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. Int J Cancer. 2018; 143(10): 2499-2504.

[10] Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer. 2006; 42(7): 895-904.

[11] Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials. J Clin Oncol. 2016; 34(19): 2221-2231.

[12] Kim HA, Lee JW, Nam SJ, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial. J Clin Oncol. 2020; 38(5): 434-443.

[13] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022; 23(3): 382-392.

[14] Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol. 2022; 33(11): 1097-1118.

[15] Yeo W, Ueno T, Lin C, et al. Treating HR+/HER2– breast cancer in premenopausal Asian women: asian Breast Cancer Cooperative Group 2019 consensus and position on ovarian suppression. Breast Cancer Res Treat. 2019; 177(3): 549-559.

[16] Fallowfield LJ. Evolution of breast cancer treatments: current options and quality-of-life considerations. Eur J Oncol Nurs. 2004; 8: S75-S82.

[17] Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008; 107(2): 167-180.

[18] Whelan TJ, Pritchard KI. Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res. 2006; 12(3): 1056s-1060s.

[19] Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018; 18(11): 1101-1112.

[20] Sloan JA, Frost MH, Berzon R, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006; 14(10): 988-998.

[21] Maratia S, Cedillo S, Rejas J. Assessing health-related quality of life in patients with breast cancer: a systematic and standardized comparison of available instruments using the EMPRO tool. Qual Life Res. 2016; 25(10): 2467-2480.

[22] Alnaim L. Health-related quality of life in women with breast cancer undergoing treatment with hormonal therapy—a review study. Eur J Breast Health. 2022; 18(4): 292-298.

[23] Xiao H, Jiang X, Chen C, Montero AJ, Diaby V. Longitudinal effects of adjuvant endocrine therapy on the quality of life of post-menopausal women with non-metastatic ER+ breast cancer: a systematic review. Pharmacoecon Open. 2018; 2(4): 359-369.

[24] Monteiro MR, Nunes N, Crespo J, et al. Patient-centered outcomes in breast cancer: description of EQ-5D-5L and EORTC-QLQ-BR23 measurements in real-world data and their association with survival. Clin Oncol (R Coll Radiol). 2022; 34(9): 608-616.

[25] Ohsumi S, Shimozuma K, Ohashi Y, et al. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1–4 years: N-SAS BC 03. Breast Cancer Res Treat. 2011; 127(1): 143-152.

[26] Takei H, Ohsumi S, Shimozuma K, et al. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat. 2012; 133(1): 227-236.

[27] Ganz PA, Cecchini RS, Julian TB, et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet North Am Ed. 2016; 387(10021): 857-865.

[28] Park C, Park SK, Woo A, Ng BP. Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study. Qual Life Res. 2022; 31(5): 1345-1357.

[29] Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 371(2): 107-118.

[30] Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018; 379(2): 122-137.

[31] Lim H, Ju Lee H, Seok Lee K, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007; 25(25): 3837-3845.

[32] Xu Y, Sun Y, Yao L, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008; 19(8): 1423-1429.

[33] Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010; 28(8): 1287-1293.

[34] Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015; 16(7): 848-858.

[35] Gu R, Jia W, Zeng Y, et al. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. BMC Cancer. 2012; 12: 161.

[36] Seibert TA, Shi L, Althouse S, et al. Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer. Sci Rep. 2024; 14(1): 1029.

[37] Ellis AJ, Hendrick VM, Williams R, Komm BS. Erratum. Correction to: Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf. 2015; 14(11): 1799-1800.

[38] MB Marttunen BCPH. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer. 2001; 84(7): 897-902.

[39] McGonigle KF, Shaw SL, Vasilev SA, et al. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol. 1998; 178(6): 1145-1150.

[40] Cancer Endocrinology Committee of Chinese Anti-Cancer Association. Guidelines for the management of endometrial lesions associated with adjuvant endocrine therapy in breast cancer (2021 edition). Chin J Pract Gynecol Obstet. 2021; 37(8): 6.

[41] Carmen A, Anne O, Monika S, et al. Does the toxicity of endocrine therapy persist into long-term survivorship?: patient-reported outcome results from a follow-up study beyond a 10-year-survival. Breast Cancer Res Treat. 2023; 198(3): 475-485.

[42] Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023; 24(1): 77-90.

[43] Treanor C, Donnelly M. A methodological review of the Short Form Health Survey 36 (SF-36) and its derivatives among breast cancer survivors. Qual Life Res. 2015; 24(2): 339-362.

[44] Ware JJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6): 473-483.

[45] McHorney CA, Ware JJ, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31(3): 247-263.

[46] EuroOol Research Foundation. EQ-5D-5L User Guide, 2019. https://euroqol.org/publications/user-guides

[47] Luo N, Liu G, Li M, et al. Estimating an EQ-5D-5L value set for China. Value Health. 2017; 20(4): 662-669.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.